Table 1.

Univariate analysis of survival in 1,181 patients by characteristics at first visit to phase I clinic

N (%)Number of deathsMedian survival, mo (95% CI)Survival rate (1 y), %
Variables1,18179510.0 (9.1–10.9)44P
Age, y
 ≤60660 (55.9)43410.9 (9.7–12.1)460.125
 >60521 (44.1)3619.1 (8.1–10.1)41
Sex
 Female594 (50.3)39210.1 (8.8–11.2)440.86
 Male587 (49.7)4039.8 (8.5–11.4)44
Tumor classification
 Breast112 (9.5)838.3 (6.6–10.8)35<0.0001
 Gastrointestinal392 (33.2)3107.4 (6.6–8.1)30
 Genitourinary110 (9.3)6712.8 (9.6–17.5)54
 Gynecologic82 (6.9)558.3 (6.8–11.0)35
 Lung/thoracic/head and neck149 (12.6)8115.5 (12.2–23.1)59
 Others336 (28.5)19915.5 (12.0–18.3)55
ECOG PSa
 0369 (31.2)23413.8 (11.6–17.1)54<0.0001
 1705 (59.7)4709.1 (8.0–10.3)41
 283 (7.0)684.1 (3.5–6.6)26
 37 (0.6)73.1 (2.9, NA)29
Liver metastases
 No683 (57.8)41312.8 (11.3–15.2)52<0.0001
 Yes498 (42.2)3827.6 (6.6–8.4)33
History of thromboembolism
 No991 (83.9)65610.8 (9.7–11.7)460.0005
 Yes190 (16.1)1397.7 (6.2–9.5)33
Platelets,a K/UL
 <140112 (9.5)848.3 (6.8–12.7)39<0.0001
 140–440928 (78.6)60310.5 (9.6–11.8)46
 >440136 (11.5)1067.9 (6.3–10.1)32
Albumin,a g/dL
 ≥3.51,041 (88.1)68410.9 (10.1–12.0)47<0.0001
 <3.5133 (11.3)1075.4 (3.9–6.8)20
Number of prior therapies
 066 (5.6)2525.3 (22.8 to NA)81<0.0001
 1113 (9.6)6516.9 (14.6–25.4)62
 2192 (16.3)1259.2 (7.7–12.0)42
 3201 (17.0)1329.4 (7.8–11.5)42
 4187 (15.8)1379.0 (7.5–10.8)37
 5+422 (35.7)3118.3 (7.5–9.7)38
Prior radiation
 No593 (50.2)39010.7 (9.5–12.4)460.028
 Yes588 (49.8)4059.2 (8.1–10.7)42
Prior surgery
 No293 (24.8)2029.9 (8.1–11.4)430.3253
 Yes888 (75.2)59310.1 (8.8–11.3)44
Number of metastatic sites
 ≤2734 (62.2)45712.4 (10.9–14.6)51<0.0001
 >2447 (37.8)3387.4 (6.7–8.1)31
LDH,a IU/L
 ≤618755 (63.9)44914.0 (12.4–16.0)55<0.0001
 >618419 (35.5)3436.8 (6.1–7.4)24
RMH scorea
 0 and 1908 (76.9)57312.3 (11.2–13.8)51<0.0001
 >1261 (22.1)2165.5 (4.8–6.6)19

Abbreviation: PS, performance status.

  • aBaseline data at first visit to phase I clinic were not available for all patients for variables including: ECOG PS (17 patients), platelets (5 patients), albumin (7 patients), LDH (7 patients), and RMH score (12 patients).